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interaction, which would typically be shown in a cell-Oxidative Modification of
free reconstitution assay. In fact, circumstantial evi-Leukocyte Adhesion dence presented in Stolen et al. (2005) suggests that it
is indeed the enzymatic activity of AOC3 that matters for
its function. First, all AOC3 antibodies with antiadhesive
properties also block its enzymatic activity. Second, if an
In this issue of Immunity, Marko Salmi and colleagues adhesion molecule is blocked by immunoneutralization,
describemice lackingAOC3, an endothelial cellmono- the effect is observed immediately, but injecting AOC3
aminooxidase that is involved in modulating leukocyte antibodies into mice raises leukocyte rolling velocity
rolling, adhesion, and migration (Stolen et al., 2005). over a 30 min period (Figure 4A in Stolen et al. [2005]),
Their data demonstrate the importance of oxidative consistent with a requirement for protein turnover that
modification of (unknown) adhesion molecules in reg- might remove an enzymatic modification. Indeed, the
ulating inflammation and lymphocyte homing. data suggest that selectin ligands may be targets of
enzymatic regulation. Neutrophil rolling velocity is in-
creased 5- to 6-fold in a model of cytokine-inducedAmino oxidase, copper-containing-3 (AOC3), also known
inflammation in venules of the cremaster muscle (Stolenas vascular adhesion molecule-1 (VAP-1), is an ectoen-
et al., 2005). This is reminiscent of the phenotype seenzyme that is constitutively expressed in adipocytes and
in E-selectin-deficient mice (Kunkel and Ley, 1996).endothelial and smooth muscle cells of most organs of
E-selectin engagement not only modulates leukocytemice and humans (Jalkanen and Salmi, 2001). Activity
rolling velocity, but also activates rolling neutrophilsis also found in blood serum, suggesting that the enzyme
(Simon et al., 2000) and results in their adhesion onmay be shed from the endothelial surface. AOC3 cata-
inflamed endothelial cells. This activation pathway islyzes oxidative deamination and produces aldehyde
redundant with chemokine-dependent neutrophil acti-groups, hydrogen peroxide, and ammonium. Although
vation, such that neutralizing chemokine receptor sig-enzymatic modifications of adhesion molecules are
naling or removing the chemokine receptor CXCR2 incommon, modification by an amino oxidase has not
mice has no effect on neutrophil recruitment unlessbeen described. Using gene targeting and homologous
E-selectin is also blocked (Smith et al., 2004). E-selectinrecombination, the authors have produced mice that
engages an unknown ligand to activate rolling neutro-lack detectable AOC3 activity from all organs tested
phils that is different from L-selectin or P-selectin Gly-(Stolen et al., 2005). Although these mice are viable and
coprotein Ligand-1 (Smith et al., 2004). Conceivably,healthy under vivariumconditions, they show interesting
absence of AOC3 impairs the neutrophil-activating ca-defects in lymphocyte homing and in the inflammatory
pacity of this interaction, which might explain the defectresponse to cytokine or autoimmune challenges. In
in neutrophil adhesion seen after 3 or 6 hr of TNF- (Stolenshort-term homing assays, AOC3/mice show reduced
et al., 2005). Slow neutrophil rolling and subsequent adhe-lymphocyte homing to mesenteric lymph nodes (MLN)
sion in inflammation requires not onlyE-selectinbut also2and spleen, which also show slightly reduced cellularity.
integrins (CD18) (Jung et al., 1998). 2 integrin-dependentWhat exactly does AOC3 do? As originally proposed,
slow neutrophil rolling is prominent when these integrinsAOC3may directly serve as an adhesionmolecule, bind-
are stabilized in a partially activated conformation (Salasing an unknown ligand (Salmi and Jalkanen, 1992). How-
ever, there are no data supporting suchadirect adhesive et al., 2004) or when their I-domain is expressed in isola-
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Figure 1. AOC3 Regulation of Leukocyte Migration May Be Dependent upon Modulation of Adhesion Molecules and/or Cell Signaling
AOC3 expressed on endothelial (green) and smooth muscle cells (not shown) and circulating in the blood may modify adhesion molecules
on the endothelial as well as the leukocyte surface to modulate leukocyte trafficking. Based on the data presented in Stolen et al. (2005),
candidate adhesion molecules include E-selectin ligands on neutrophils (left) and L-selectin ligands on high endothelial cells (right). In
addition, byproducts generated by AOC3 enzymatic activity such as H2O2 may regulate endothelial and/or leukocyte cell signals necessary
for transmigration, including MMP activation, protein tyrosine phosphatase inhibition, and/or gene expression.
tion (Knorr and Dustin, 1997). This means that there nous addition of H2O2 to VAP-1-expressing rabbit cardiac
endothelium does not enhance lymphocyte rolling andis ample room for AOC3-dependent modifications of
neutrophil rolling and adhesion beyond just modifying adhesion. However, transmigration was not examined.
AOC3 is only one among many sources of H2O2. DuringE-selectin ligands. Some possibilities are shown in Fig-
ure 1. VCAM-1-dependent lymphocyte migration, VCAM-1
signaling in endothelial cells activates NADPH oxidase,Lymphocyte homing to peripheral lymph nodes and
Peyer’s patches is largely L-selectin dependent (von An- a plasma membrane enzyme complex that generates
low levels of extracellular ROS that have intracellulardrian and McKay, 2000). L-selectin ligands in secondary
lymphoid organs are fucosylated, sialylated, and sulfated and cell surface effects. Inhibiting NADPH oxidase ex-
pression or scavengingROSblocks VCAM-1-dependentcarbohydrates that are collectively known as PNAd, or
Peripheral Node Addressins. Interestingly, mild oxidation lymphocyte migration (Matheny et al., 2000). In analogy
to these observations, AOC3-generated H2O2 may alsoof PNAd such as might be expected from the action of
AOC3 has been described to produce a Schiff base and regulate lymphocyte migration.
Even though the current paper does not providethus stabilize L-selectin interactions (Puri and Springer,
1996). The data reported in Stolen et al. (2005) are consis- mechanistic insight into how AOC3/VAP-1 really works,
it unequivocally shows that this enzymemodulates neu-tent with L-selectin ligands beingmodified by AOC3 activ-
ity, which may increase their binding to L-selectin. How- trophil and lymphocyte trafficking. The authors show
reduced disease incidence and lethality in a model ofever, L-selectin is not involved in lymphocyte homing
to the spleen, which is also reduced in AOC3/ mice. autoimmune diabetes, reduced leukocyte infiltration in
a model of peritonitis, but unchanged lethality in re-This suggests that AOC3 may have other unknown ef-
fects. sponse to Yersinia infection. Because the inflammatory
and immune defects are mild in AOC3/ mice, it isInterestingly, Stolen et al. (2005) found an even stronger
71% reduction in neutrophil transmigration compared to a possible that blocking this enzyme could have useful
anti-inflammatory effects. Whether or not therapeutic50% reduction in firm adhesion, suggesting that an AOC3-
dependent modification or interaction primes neutrophils trials are successful, the availability of AOC3/ mice
opens the door for conducting investigations into thefor transendothelial migration. Potentially, H2O2 generated
by AOC3 enzymatic activity may modulate lymphocyte molecularmechanisms of AOC3 action in leukocyte traf-
ficking.migration. Salmi et al. (2001) demonstrated that exoge-
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